Hai-Zhou Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hai-Zhou Wang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Gu He
Sichuan University and Collaborative Innovation Center for Biotherapy
1 shared publication - Hai-Ti Yu
Sichuan University
1 shared publication - Hao Zeng
Department of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, China
1 shared publication - Jianbang Liu
Department of Urology, Institute of Urology
1 shared publication - Jiyan Liu
Sichuan University
1 shared publication - Long Huang
School of Ecology and Environment, Zhengzhou University, Zhengzhou 450001, China
1 shared publication
Latest Publications
- 16 November 2018
- Published by Springer Nature in Journal of Mountain Science
- Vol. 15 (11) , 2347-2364
Flow variability along a vegetated natural stream under various sediment transport rates
- 16 November 2018
- Published by Springer Nature in Journal of Mountain Science
- Vol. 15 (11) , 2347-2364
Flow variability along a vegetated natural stream under various sediment transport rates
- Open Access
- 24 October 2018
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 54 (1) , 348-360
Expression and epigenetic regulatory mechanism of BNIP3 in clear cell renal cell carcinoma
The majority of clear cell renal cell carcinomas (ccRCCs) are caused by an accumulation of hypoxia‑inducible factor (HIF) and the overexpression of downstream genes in response to the von Hippel‑Lindau (VHL) gene becoming inactivated. In the present study, our hypothesis was that BNIP3, a gene positioned downstream of HIF, would be expressed at a higher level in ccRCC; however, instead, lower levels of BNIP3 expression were identified in RCC tumor tissues compared with adjacent non‑tumor tissues. These changes were associated with lower levels of VHL, and higher levels of HIF and vascular endothelial growth factor. BNIP3 was also undetectable in three investigated RCC cell lines (786‑O, ACHN, A498) and GRC‑1‑1 cells. Methylation of the BNIP3 promoter was not detected, and neither did treatment with a methylation inhibitor cause cell proliferation. However, treatment with a histone deacetylation inhibitor, trichostatin A (TSA), inhibited cultured RCC cell proliferation, promoted apoptosis and restored BNIP3 expression. Furthermore, histone deacetylation of the BNIP3 promoter was identified in ACHN and 786‑O cells, and the acetylation status was restored following TSA treatment. Taken together, the results of the present study suggest that histone deacetylation, but not methylation, is most likely to cause BNIP3 inactivation in RCC. The data also indicated that restoration of BNIP3 expression by a histone deacetylation inhibitor led to growth inhibition and apoptotic promotion in RCC.
- 24 October 2018
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 54 (1) , 348-360
Open AccessExpression and epigenetic regulatory mechanism of BNIP3 in clear cell renal cell carcinoma
The majority of clear cell renal cell carcinomas (ccRCCs) are caused by an accumulation of hypoxia‑inducible factor (HIF) and the overexpression of downstream genes in response to the von Hippel‑Lindau (VHL) gene becoming inactivated. In the present study, our hypothesis was that BNIP3, a gene positioned downstream of HIF, would be expressed at a higher level in ccRCC; however, instead, lower levels of BNIP3 expression were identified in RCC tumor tissues compared with adjacent non‑tumor tissues. These changes were associated with lower levels of VHL, and higher levels of HIF and vascular endothelial growth factor. BNIP3 was also undetectable in three investigated RCC cell lines (786‑O, ACHN, A498) and GRC‑1‑1 cells. Methylation of the BNIP3 promoter was not detected, and neither did treatment with a methylation inhibitor cause cell proliferation. However, treatment with a histone deacetylation inhibitor, trichostatin A (TSA), inhibited cultured RCC cell proliferation, promoted apoptosis and restored BNIP3 expression. Furthermore, histone deacetylation of the BNIP3 promoter was identified in ACHN and 786‑O cells, and the acetylation status was restored following TSA treatment. Taken together, the results of the present study suggest that histone deacetylation, but not methylation, is most likely to cause BNIP3 inactivation in RCC. The data also indicated that restoration of BNIP3 expression by a histone deacetylation inhibitor led to growth inhibition and apoptotic promotion in RCC.